Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Pfizer offers an annual dividend yield of 6.98%, or $1.72 a year. Here's how investors can pocket a regular $500 monthly.

Investing.com -- Metsera Inc (NASDAQ:MTSR) stock rose 13% Tuesday as pharmaceutical giants Novo Nordisk (NYSE:NVO) and Pfizer ...